NVCR - NASDAQ

NovoCure Limited

NovoCure Limited

NVCRยทNASDAQ

$16.15

+2.1%
HealthcareMedical - Instruments & Supplies

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.87B
EPS-1.2200
P/E Ratio-13.24
Earnings Date07/23/2026
NovoCure Limited

NovoCure Limited Fair Value Envelope

NVCR ยท NASDAQ

Our analysis suggests that NVCR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $16.15, this represents a potential HIDDEN relative to our calculated worth for NovoCure Limited.

HIDDEN
Intrinsic Value
Current Price: $16.15

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$235.0M
+ Cash & Equivalents$103.4M
Firm Value-$131.6M
- Debt$290.0M
Equity Value-$421.6M
/ Shares Outstanding115,820,940B
DCF Value-$4
OVERVALUED BY 123%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$44.5M
-$40.3M
-$36.6M
-$33.1M
-$30.1M
-$27.3M
-$24.7M
-$22.4M
-$20.3M
-$18.4M
Maintenance CapEx
-$4.8M
-$4.4M
-$4.0M
-$3.6M
-$3.3M
-$3.0M
-$2.7M
-$2.4M
-$2.2M
-$2.0M
Owner Earnings
-$49.3M
-$44.7M
-$40.5M
-$36.7M
-$33.3M
-$30.2M
-$27.4M
-$24.8M
-$22.5M
-$20.4M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$45.6M
-$38.3M
-$32.2M
-$27.0M
-$22.7M
-$19.0M
-$16.0M
-$13.4M
-$11.3M
-$9.5M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your NVCR research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.